Bal Pharma Limited (BALPHARMA.NS)
INR 120.5
(-0.08%)
INR 120.5
(-0.08%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.39 Billion INR | 6.6% |
| 2022 | 1.3 Billion INR | 22.82% |
| 2021 | 1.06 Billion INR | -4.73% |
| 2020 | 1.11 Billion INR | -7.04% |
| 2019 | 1.2 Billion INR | -2.5% |
| 2018 | 1.23 Billion INR | 12.31% |
| 2017 | 1.09 Billion INR | 18.1% |
| 2016 | 931.09 Million INR | 9.48% |
| 2015 | 850.48 Million INR | 81.8% |
| 2014 | 467.82 Million INR | -7.76% |
| 2013 | 507.19 Million INR | 10.19% |
| 2012 | 460.3 Million INR | -9.07% |
| 2011 | 506.2 Million INR | -13.64% |
| 2010 | 586.15 Million INR | 7.39% |
| 2009 | 545.8 Million INR | 15.72% |
| 2008 | 471.68 Million INR | 4.47% |
| 2007 | 451.49 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 1.39 Billion INR | 0.0% |
| 2023 Q2 | 1.41 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 1.39 Billion INR | 6.6% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.37 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.3 Billion INR | 22.82% |
| 2022 Q4 | 1.3 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 1 Billion INR | 0.0% |
| 2021 FY | 1.06 Billion INR | -4.73% |
| 2021 Q4 | 1.06 Billion INR | 0.0% |
| 2020 Q4 | 1.11 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 1.17 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 1.11 Billion INR | -7.04% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 1.2 Billion INR | -2.5% |
| 2019 Q2 | 1.14 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 1.2 Billion INR | 0.0% |
| 2018 Q4 | 1.23 Billion INR | 0.0% |
| 2018 FY | 1.23 Billion INR | 12.31% |
| 2017 FY | 1.09 Billion INR | 18.1% |
| 2017 Q4 | 1.09 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 931.09 Million INR | 9.48% |
| 2016 Q4 | 931.09 Million INR | 0.0% |
| 2016 Q2 | 854.1 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 850.48 Million INR | 81.8% |
| 2015 Q4 | 850.48 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 700.15 Million INR | 0.0% |
| 2014 Q2 | 480.19 Million INR | 0.0% |
| 2014 FY | 467.82 Million INR | -7.76% |
| 2014 Q4 | 467.82 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q2 | 470 Million INR | 0.0% |
| 2013 Q4 | 507.19 Million INR | 0.0% |
| 2013 FY | 507.19 Million INR | 10.19% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q2 | 476.03 Million INR | 0.0% |
| 2012 FY | 460.3 Million INR | -9.07% |
| 2012 Q4 | 460.3 Million INR | 0.0% |
| 2011 Q4 | 506.2 Million INR | 0.0% |
| 2011 FY | 506.2 Million INR | -13.64% |
| 2010 FY | 586.15 Million INR | 7.39% |
| 2009 FY | 545.8 Million INR | 15.72% |
| 2008 FY | 471.68 Million INR | 4.47% |
| 2007 FY | 451.49 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 2.379% |
| Ind-Swift Limited | 10.13 Billion INR | 86.228% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 58.041% |
| Sakar Healthcare Limited | 793.51 Million INR | -75.987% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 97.899% |
| Innova Captab Limited | 2.45 Billion INR | 43.025% |
| Divi's Laboratories Limited | 30 Million INR | -4554.947% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -2937.023% |
| Morepen Laboratories Limited | 289.99 Million INR | -381.559% |
| Mankind Pharma Limited | 2.07 Billion INR | 32.593% |
| Sequent Scientific Limited | 4.87 Billion INR | 71.366% |
| Wanbury Limited | 1.16 Billion INR | -19.886% |
| Laurus Labs Limited | 25.77 Billion INR | 94.582% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 78.027% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -714.371% |
| Alembic Limited | 91.5 Million INR | -1426.212% |
| Hikal Limited | 8.17 Billion INR | 82.919% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 72.787% |
| Neuland Laboratories Limited | 953.89 Million INR | -46.398% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 63.023% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 88.655% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -326.277% |
| Themis Medicare Limited | 957.92 Million INR | -45.783% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 82.635% |
| Lupin Limited | 29.21 Billion INR | 95.22% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -7980.102% |
| Wockhardt Limited | 23.56 Billion INR | 94.073% |
| Vaishali Pharma Limited | 134.91 Million INR | -935.061% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 51.044% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -1461.888% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 96.189% |
| FDC Limited | 205.18 Million INR | -580.598% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 93.025% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -341.276% |
| Eris Lifesciences Limited | 27.81 Billion INR | 94.979% |
| Venus Remedies Limited | 413.3 Million INR | -237.886% |
| ZIM Laboratories Limited | 1.08 Billion INR | -28.325% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -39.872% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -6988.751% |
| Shilpa Medicare Limited | 9.37 Billion INR | 85.102% |
| Albert David Limited | 33.24 Million INR | -4100.963% |
| Ajanta Pharma Limited | 352.8 Million INR | -295.829% |
| Hester Biosciences Limited | 2.44 Billion INR | 42.856% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -114.856% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 86.194% |
| Gufic Biosciences Limited | 3.32 Billion INR | 58.053% |
| Windlas Biotech Limited | 36.41 Million INR | -3735.441% |
| Procter & Gamble Health Limited | 95.6 Million INR | -1360.757% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -345.417% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -41.786% |
| Granules India Limited | 13.15 Billion INR | 89.381% |
| Aarti Drugs Limited | 5.64 Billion INR | 75.251% |
| Alkem Laboratories Limited | 14.18 Billion INR | 90.155% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 95.734% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -12990.401% |
| Medicamen Biotech Limited | 308.17 Million INR | -353.151% |
| Unichem Laboratories Limited | 2.47 Billion INR | 43.58% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -472.581% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -31717.817% |
| Valiant Laboratories Limited | 767.08 Million INR | -82.051% |
| Orchid Pharma Limited | 1.35 Billion INR | -3.305% |
| Medico Remedies Limited | 80.5 Million INR | -1634.677% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -740.162% |
| Ipca Laboratories Limited | 14.38 Billion INR | 90.291% |
| Brooks Laboratories Limited | 56.41 Million INR | -2375.202% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -92.654% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.739% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 96.528% |
| NATCO Pharma Limited | 3.71 Billion INR | 62.379% |
| Suven Life Sciences Limited | 7.09 Million INR | -19577.103% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 27.804% |
| Strides Pharma Science Limited | 25.16 Billion INR | 94.451% |
| Indoco Remedies Limited | 6.71 Billion INR | 79.218% |
| Alpa Laboratories Limited | 52.46 Million INR | -2561.744% |
| Lasa Supergenerics Limited | 220.76 Million INR | -532.574% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -128.37% |